Latest Clinical pharmacology Stories

Impax Laboratories, Inc. Continues to Ignore FDA Warnings, Causing a Delay in Bringing a New Drug to Market; Robbins Arroyo LLP Investigates on Behalf of Impax Shareholders

2013-03-14 20:21:50

SAN DIEGO and HUNTERSVILLE, N.C., March 14, 2013 /PRNewswire/ -- Shareholder rights firm Robbins Arroyo LLP is investigating whether officers and directors of Impax Laboratories, Inc. (NASDAQ: IPXL) breached their fiduciary duties to shareholders by failing to correct the Company's inadequate quality controls and deficiencies in its manufacturing processes. (Logo: http://photos.prnewswire.com/prnh/20130103/MM36754LOGO) The FDA Notifies the Company of Its "Significant Violations...

NW Bio Establishes Cross-Border Manufacturing And Distribution For DCVax® In Europe

2013-03-12 08:29:45

Approvals Expanding the Scope of German Manufacturing Are Key Steps BETHESDA, Md., March 12, 2013 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax(®) personalized immune therapies for solid tumor cancers, announced today that the Company has taken a key step in building Europe-wide arrangements for manufacturing and distribution of DCVax. This represents a major area of competitive differentiation and strength for NW Bio....

Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Impax Laboratories Inc.

2013-03-06 08:27:29

NEW YORK, March 6, 2013 /PRNewswire/ -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Impax Laboratories Inc. ("Impax" or the "Company") (NasdaqGS: IPXL). The investigation focuses on whether the Company and its executives violated federal securities laws. On March 4, 2013, Shares of Impax dropped $4.10, or 20.5 percent, to $15.90 in aftermarket trading following the Company's announcement...

BioDrain Announces Additional Trial Installations and Sales of BioDrain STREAMWAY® Systems Across the U.S.

2013-03-05 08:24:19

MINNEAPOLIS, March 5, 2013 /PRNewswire/ -- BioDrain Medical, Inc., (OTCQB: BIOR) ("BioDrain"), producer of the FDA approved STREAMWAY® System for automated, direct-to-drain surgical fluid disposal that reduces the risk of exposure to hazardous waste, announced today that it has completed additional trial installations and sales over the last sixty days of its STREAMWAY® Systems into hospitals and surgical centers in various states including New York, Michigan, Minnesota and...

US Spending on Traditional Prescription Drugs Fell in 2012 for First Time on Record

2013-03-05 00:20:52

- Hepatitis C accounted for higher percentage drug spend increase than any other major disease in 2012. ST. LOUIS, March 5, 2013 /PRNewswire/ -- For the first time in more than 20 years, there was a decrease in 2012 U.S. spending on traditional prescription drugs -- primarily pills people take to treat more common diseases such as high cholesterol and high blood pressure -- according to new data released today by Express Scripts (NASDAQ: ESRX). (Logo:...

Groupe Athena, Inc. Enters Multi Year Contractual Relationship With Major Bangladesh Pharmaceutical Manufacturer

2013-03-04 12:27:23

MUMBAI, India, March 4, 2013 /PRNewswire/ -- Groupe Athena, Inc. (OTCPink:GATA) announced today they have entered into a multiyear contract with Eskayef Bangladesh LTD., a leading Indian pharmaceutical manufacturer. Under the terms of the agreement Groupe Athena will assist Eskayef in obtaining FDA approval for their Bangladesh manufacturing facility during the first stage, and assist with U.S approval of individual drugs in subsequent stages of the agreement. The contract could...

Covalon Announces First Quarter Financial Results

2013-03-01 16:25:27

MISSISSAUGA, ON, March 1, 2013 /CNW/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced financial results for its first quarter ended December 31, 2012. Revenue for the quarter was $572,006, down 17%, operating expenses were $1,018,752, down 8% and the net loss for the first quarter was $794,481 or $0.01 per share compared to $800,054 or $0.01 per share in the first quarter of the previous year. During...

Research Foundations Collaborate To Fund Repository Of Promising CNS-Active Compounds

2013-02-28 08:31:00

Collaborative CNS Screening Initiative (CCSI) Aims to Share Knowledge and Speed Drug Discovery NEW YORK, Feb. 28, 2013 /PRNewswire-USNewswire/ -- The Alzheimer's Drug Discovery Foundation (ADDF), Beyond Batten Disease Foundation (BBDF) and the National Multiple Sclerosis Society today announced a funding collaboration to support the creation of the Collaborative CNS Screening Initiative (CCSI), a central repository of chemical compounds that have shown significant Central Nervous...

GPMG Unveils a Quality System Product Designed for Initial Importers of Medical Devices

2013-02-27 08:29:26

GPMG, a medical device consulting firm, unveiled a new product to help Initial Importers of medical devices comply with FDA regulations. The design of the system allows for immediate implementation and fits varying organizational structures. GARDNER, Mass., Feb. 27, 2013 /PRNewswire/ -- Global Pacific Manufacturing Group LLC (www.gpacmfg.com), has developed a practical and cost-effective quality system to help the thousands of current and future Initial Importers be FDA compliant. A...

FDA's Rick Friedman and Rebecca Rodriguez Confirmed as Closing Plenary Speakers for PDA Human Factors Workshop

2013-02-26 12:28:07

BETHESDA, Md., Feb. 26 2013 /PRNewswire-USNewswire/ -- The Parenteral Drug Association (PDA) announced today that Richard Friedman, Associate Director OMPQ, U.S. FDA, and Rebecca Rodriguez, Consumer Safety Officer, U.S. FDA, have been confirmed to deliver the closing plenary talks at the 2013 Human Factors and Human Error Reduction Workshop. The workshop will take place on April 17 - 18, 2013 at the Peabody Hotel in Orlando, Fla. (Logo:...